Vermillion Inc. (NASDAQ:VRML) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 202,005 shares, a decrease of 60.4% from the August 31st total of 510,215 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily volume of 27,996 shares, the short-interest ratio is currently 7.2 days.

Shares of Vermillion (NASDAQ:VRML) opened at 1.24 on Wednesday. Vermillion has a one year low of $0.92 and a one year high of $2.20. The stock has a 50 day moving average price of $1.33 and a 200-day moving average price of $1.30. The company’s market capitalization is $64.76 million.

Vermillion (NASDAQ:VRML) last issued its earnings results on Wednesday, August 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Vermillion had a negative return on equity of 121.09% and a negative net margin of 985.56%. Equities research analysts predict that Vermillion will post ($0.29) earnings per share for the current fiscal year.

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

5 Day Chart for NASDAQ:VRML

Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with's FREE daily email newsletter.